Applied Pharmacoeconomic and Outcomes Research Forum

March 7th 2016
1. AMCP Dossiers: Useful for Decision Making or Not? A Debate
2. Biologics: Drawing (or Crossing) the line of Cost vs. Benefit: A Case in Oncology
3. Quality Adjusted Life Years (QALY’s) for Decision Making: Views from Canada & the US
4. Using Large Databases to Inform Decision Making: Experience in Three Health Care Systems
5. Real World Data for Decision Making: Moving Beyond Clinical Trials
6. Pharmacoeconomics of Pharmacogenomics
7. Pharmacoeconomics & Pricing: Now & After Health Care Reform
8. What is the Business Case for Quality Improvement Initiatives?
10. Biosimilars: Challenges and Opportunities for All.
11. Patient Reported Outcomes: Useful for Whom?
Forum Objectives

- Discuss commonly encountered obstacles to conducting or utilizing results of PE studies for decision making
- Explore solutions from various perspectives
  - Managed Care
  - Government
  - Pharmaceutical/Biotech Firms
  - Medical Centers
  - Academia
- Create an environment & foundation to foster larger PE/Outcomes Research Interest Group
Steering Committee

Michael S. Broder MD, MSHS  
Partnership for Health Analytic Research

Charles Daniels, RPh, PhD  
UCSD Health Department of Pharmacy

Jan D. Hirsch, RPh, PhD  
UCSD, Skaggs School of Pharmacy & Pharmaceutical Sciences

Mirta Millares, PharmD, FCSHP, FASHP  
Kaiser Permanente – CA Region

Anthony P. Morreale, Pharm.D., MBA, BCPS  
PBM Services, Department of Veterans Affairs

Michael Pollock  
PPD

Robert Schoenhaus, PharmD  
Sharp HealthCare
Sponsors - Thanks!

PE Forum Sponsorship Fund

Exhibitors

Abbvie
Allergan
Teva Pharmaceutical Industries Ltd.
Health Services Research
Applications & Challenges Across Healthcare Systems
Quiz Time!
Smart Phones Down
Laptops & Tablets Closed
1. According to the World Health Organization, as of 2011, how many different types of diseases and related health problems exist?

a. 823  
b. 12,420  
c. 101,222
1. According to the World Health Organization, as of 2011, how many different types of diseases and related health problems exist?

a. 823
b. 12,420
c. 101,222

Pharma Trivia

2. Which state employs the most people directly involved with drug research & development?
   a. California
   b. New Jersey
   c. Massachusetts
   d. New York

2. Which state employs the most people directly involved with drug research & development?

a. California
b. New Jersey
c. Massachusetts
d. New York

2. Which state employs the most people directly involved with drug research & development?

a. California
b. New Jersey
c. Massachusetts

d. New York

28,000 (2010)

3. How many clinical studies are being conducted worldwide according to clinicaltrials.gov?

a. 28,455  
b. 78,333  
c. 139,372  
d. 205,201

https://clinicaltrials.gov/ct2/resources/trends
3. How many clinical studies are being conducted worldwide according to clinicaltrials.gov?

a. 28,455  
b. 78,333  
c. 139,372  
d. 205,201
Pharma Trivia

3. How many clinical studies are being conducted worldwide according to clinicaltrials.gov?

a. 28,455
b. 78,333
c. 139,372
d. 205,201

In 192 countries.

https://clinicaltrials.gov/ct2/resources/trends
Pharma Trivia

4. How much higher is the average wage for bioscience workers compared to other private sector employees?
   a. 45%
   b. 79%
   c. 90%
   d. 110%

Pharma Trivia

4. How much higher is the average wage for bioscience workers compared to other private sector employees?
   a. 45%
   b. 79%
   c. 90%
   d. 110%

4. How much higher is the average wage for bioscience workers compared to other private sector employees?

a. 45%

b. 79%

c. 90%

d. 110%

$82,697 (2010)

5. Of the drugs in the FDA's Orange Book (i.e., list of approved drugs), what percentage have generic counterparts?

a. 32%
b. 79%
c. 90%
d. 110%

5. Of the drugs in the FDA's Orange Book (i.e., list of approved drugs), what percentage have generic counterparts?

a. 32%
b. 79%
c. 90%
d. 110%

5. Of the drugs in the FDA's Orange Book (i.e., list of approved drugs), what percentage have generic counterparts?

a. 32%

b. 79%

c. 90%

d. 110%

Pharma Trivia

More after the Break!
Overview Health Services Research Umbrella & Inclusion of Pharmacoeconomic Principles
Anthony P Morreale, PharmD, MBA, BCPS
Assistant Chief Consultant for Clinical Pharmacy Services and Healthcare Services Research
Pharmacy Benefits Management, Department of Veterans Affairs

Perspectives and Case Examples

Integrated Healthcare System
Heather Ourth, Pharm.D., BCPS, CGP
Program Manager: Clinical Pharmacy Practice Program and Outcomes Assessment
Pharmacy Benefits Management, Department of Veterans Affairs

Medical Center
Katie Derry, Pharm.D., BCPS
Pharmacy Specialist, Clinical Pharmacoeconomics and Outcomes
UC San Diego Health System

Medical Group
Andrea De Coro, PharmD
Executive Director, Clinical Pharmacy Services and Performance Improvement
MemorialCare Medical Foundation
6. In 1667, a human received one of the first blood transfusions. What was the source of the blood?

a. Lamb
b. Rabbit
c. Rat
d. Dog

http://lifeinthefastlane.com/funtabulously-frivolous-friday-five-031/
Pharma Trivia

6. In 1667, a human received one of the first blood transfusions. What was the source of the blood?
   a. Lamb
   b. Rabbit
   c. Rat
   d. Dog

http://lifeinthefastlane.com/funtabulously-frivolous-friday-five-031/
Pharma Trivia

6. In 1667, a human received one of the first blood transfusions. What was the source of the blood?
   a. Lamb
   b. Rabbit
   c. Rat
   d. Dog

http://lifeinthefastlane.com/funtabulously-frivolous-friday-five-031/
Pharma Trivia

7. The first of which class of drug was extracted from the venom of the Brazilian Arrow-headed viper?

a. ARB
b. 5HT3
c. NNRTI
d. ACE

http://lifeinthefastlane.com/funtabulously-frivolous-friday-five-031/
Pharma Trivia

7. The first of which class of drug was extracted from the venom of the Brazilian Arrow-headed viper?

a. ARB  
b. 5HT3  
c. NNRTI  
d. ACE

http://lifeinthefastlane.com/funtabulously-frivolous-friday-five-031/

Angiotensin-Converting Enzyme Inhibitors – from bradykinin
8. The biotech age began in 1973, when Stanley Cohen & Genentech founder Herbert Boyer inserted DNA from an animal into E. coli bacteria. What was the animal?

a. Frog
b. Newt
c. Mouse
d. Rabbit

8. The biotech age began in 1973, when Stanley Cohen & Genentech founder Herbert Boyer inserted DNA from an animal into E. coli bacteria. What was the animal?

a. Frog  
b. Newt  
c. Mouse  
d. Rabbit
Pharma Trivia

8. The biotech age began in 1973, when Stanley Cohen & Genentech founder Herbert Boyer inserted DNA from an animal into E. coli bacteria. What was the animal?

a. Frog
b. Newt
c. Mouse
d. Rabbit

9. Warfarin was discovered in clover. What is it named for?
   a. Willamette American River Fortune
   b. Wharf Alliance of Research Federation
   c. Wisconsin Alumni Research Foundation

Pharma Trivia

9. Warfarin was discovered in clover. What is it named for?
   a. Willamette American River Fortune
   b. Wharf Alliance of Research Federation
   c. Wisconsin Alumni Research Foundation

10. Cyclosporine was discovered partly as a result of what travel policy at a large Pharma company?

- a. Digging on location
- b. Collecting hotel soaps
- c. Tasting local wines
- d. Using airport shuttles

10. Cyclosporine was discovered partly as a result of what travel policy at a large Pharma company?

a. Digging on location  
b. Collecting hotel soaps  
c. Tasting local wines  
d. Using airport shuttles
Pharma Trivia

10. Cyclosporine was discovered partly as a result of what travel policy of a Pharma company?

a. Digging on location
b. Collecting hotel soaps
c. Tasting local wines
d. Using airport shuttles

10. Cyclosporine was discovered partly as a result of what travel policy at a large Pharma company? 

a. Digging on location  
b. Collecting hotel soaps  
c. Tasting local wines  
d. Using airport shuttles

Overview Health Services Research Umbrella & Inclusion of Pharmacoeconomic Principles
Anthony P Morreale, PharmD, MBA, BCPS
Assistant Chief Consultant for Clinical Pharmacy Services and Healthcare Services Research Pharmacy Benefits Management, Department of Veterans Affairs

Perspectives and Case Examples

Integrated Healthcare System
Heather Ourch, Pharm.D., BCPS, CGP
Program Manager: Clinical Pharmacy Practice Program and Outcomes Assessment Pharmacy Benefits Management, Department of Veterans Affairs

Medical Center
Katie Derry, Pharm.D., BCPS
Pharmacy Specialist, Clinical Pharmacoconomics and Outcomes
UC San Diego Health System

Medical Group
Andrea De Coro, PharmD
Executive Director, Clinical Pharmacy Services and Performance Improvement
MemorialCare Medical Foundation